Promising effects of nanomedicine in cancer drug delivery

References

• Alexis F, Pridgen EM, Langer R, et al. Nanoparticle technologies for cancer therapy. Drug Deliv. 2010;197:55–86.
   Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20.
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161–171.
   PubMed Web of Science ®Google Scholar
• Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotechnol. 2008;3:131–132.
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688–701.
   PubMed Web of Science ®Google Scholar
• Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615–627.
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2010;62:122–149.
   PubMed Web of Science ®Google Scholar
• Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93–102.
   PubMed Web of Science ®Google Scholar
• Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro-and nanoscale drug delivery carriers. J Control Release. 2007;121:3–9.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002;54:135–147.
   PubMed Web of Science ®Google Scholar
• Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev. 2008;60:939–954.
   PubMed Web of Science ®Google Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165–1170.
   PubMed Web of Science ®Google Scholar
• Sa LTM, Albernaz Mde S, Patricio BF, et al. Biodistribution of nanoparticles: initial considerations. J Pharm Biomed Anal. 2012;70:602–604.
   PubMed Web of Science ®Google Scholar
• Kazunori K, Kwon GS, Yokoyama M, et al. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1993;24:119–132.
   Web of Science ®Google Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24:1.
   PubMed Web of Science ®Google Scholar
• Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 2007;7:1542–1550.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nature Nanotech. 2007;2:469–478.
   PubMed Web of Science ®Google Scholar
• Serda RE, Ferrati S, Godin B, et al. Mitotic trafficking of silicon microparticles. Nanoscale. 2009;1:250–259.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hamad I, Andresen TL, et al. Methylation of the phosphate oxygen moiety of phospholipid-methoxy (polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006;20:2591–2593.
   PubMed Web of Science ®Google Scholar
• Hamad I, Christy Hunter A, Rutt KJ, et al. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol. 2008;45:3797–3803.
   PubMed Web of Science ®Google Scholar
• Chow EK-H, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sc Transl Med. 2013;5:216rv4–216rv4.
   PubMed Web of Science ®Google Scholar
• Xu X, Ho W, Zhang X, et al. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med. 2015;21:223–232.
   PubMed Web of Science ®Google Scholar
• Wakaskar RR, Bathena SP, Tallapaka SB, et al. Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration. Pharm Res. 2015;32:1028–1044.
   PubMed Web of Science ®Google Scholar
• Ambardekar VV, Wakaskar RR, Sharma B, et al. The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG (5K). Biomaterials. 2013;34:4839–4848.
   PubMed Web of Science ®Google Scholar
• Wakaskar RR. Effect of peripheral shell cross-linking on the efficacy of a hydrophobic vascular disrupting agent physically loaded in core-shell polymeric micelles. University of Nebraska Medical Center; 2015.
   Google Scholar
• Almeida JPM, Chen AL, Foster A, et al. In vivo biodistribution of nanoparticles. Nanomedicine (Lond). 2011;6:815–835.
   PubMed Web of Science ®Google Scholar
• Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small. 2013;9:1521–1532.
   PubMed Web of Science ®Google Scholar
• Ernsting MJ, Murakami M, Roy A, et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013;172:782–794.
   PubMed Web of Science ®Google Scholar
• Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21:107–116.
   Web of Science ®Google Scholar
• van Nostrum CF. Covalently cross-linked amphiphilic block copolymer micelles. Soft Matter. 2011;7:3246–3259.
   Web of Science ®Google Scholar
• Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41:2971–3010.
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63:170–183.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
   PubMed Web of Science ®Google Scholar
• Barenholz YC. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72:191–202.
   PubMed Web of Science ®Google Scholar
• Kim T-Y, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708–3716.
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172–176.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515.
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Miranda OR, Moyano DF, et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011;6:e24374.
   PubMed Web of Science ®Google Scholar
• Gaumet M, Vargas A, Gurny R, et al. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1–9.
   PubMed Web of Science ®Google Scholar
• Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5:496–504.
   PubMed Web of Science ®Google Scholar
• Wakaskar R. Types of nanocarriers–formulation method and applications. J Bioequiv Avail. 2017;9:e77.
   Google Scholar
• Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–2387.
   PubMed Web of Science ®Google Scholar
• Wakaskar RR. General overview of lipid–polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target. 2017 [Aug 18]; [8 p.]. DOI:10.1080/1061186X.2017.1367006
   Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
   PubMed Web of Science ®Google Scholar
• Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63:623–639.
   PubMed Web of Science ®Google Scholar
• Wakaskar RR. Passive and active targeting in tumor microenvironment. Int J Drug Develop Res. 2017;9:37–41.
   Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Ge Z, Liu S. Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chem Soc Rev. 2013;42:7289–7325.
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128ra39–128ra39.
   PubMed Web of Science ®Google Scholar
• Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharma. 2009;6:659–668.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Hang C, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067–1070.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994;269:3198–3204.
   PubMed Web of Science ®Google Scholar
• Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16:237–246.
   PubMed Web of Science ®Google Scholar
• Pan J, Feng S-S. Targeted delivery of paclitaxel using folate-decorated poly (lactide)–vitamin E TPGS nanoparticles. Biomaterials. 2008;292663–2672.
   PubMed Web of Science ®Google Scholar
• Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomed Nanotechnol Biol Med. 2010;6:9–24.
   PubMed Web of Science ®Google Scholar
• Chen WC, Zhang AX, Li S-D. Limitations and niches of the active targeting approach for nanoparticle drug delivery. Eur J Nanomed. 2012;4:89–93.
   Google Scholar
• Wakaskar RR. Challenges pertaining to adverse effects of drugs. Int J Drug Develop Res. 2017;9:1–2.
   Google Scholar
• Wakaskar RR. Brief overview of nanoparticulate therapy in cancer. Journal of Drug Targeting 2017 [Jul 4]; [4 p.]. DOI:10.1080/1061186X.2017.1347175
   Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. A decade of change. Nat Rev Drug Discov. 2012;11:17–18.
   PubMed Web of Science ®Google Scholar
• Schütz CA, Juillerat-Jeanneret L, Mueller H, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine. 2013;8:449–467.
   PubMed Web of Science ®Google Scholar
• Kou L, Luo Y, Liu X, et al. Effects of mild heat treatment on microbial growth and product quality of packaged fresh‐cut table grapes. J Food Sci. 2007;72:S567–S573.
   PubMed Web of Science ®Google Scholar
• Mousavi SR, Rezaei M. Nanotechnology in agriculture and food production. J Appl Environ Biol Sci. 2011;1:414–419.
   Google Scholar
• Rashidi L, Khosravi-Darani K. The applications of nanotechnology in food industry. Critic Rev Food Sci Nutrit. 2011;51:723–730.
   PubMed Web of Science ®Google Scholar
• Taglietti A, Arciola CR, D'Agostino A, et al. Antibiofilm activity of a monolayer of silver nanoparticles anchored to an amino-silanized glass surface. Biomaterials. 2014;35:1779–1788.
   PubMed Web of Science ®Google Scholar
• Eleftheriadou M, Pyrgiotakis G, Demokritou P. Nanotechnology to the rescue: using nano-enabled approaches in microbiological food safety and quality. Curr Opin Biotechnol. 2017;44:87–93.
   PubMed Web of Science ®Google Scholar
• Leoni L, Desai TA. Nanoporous biocapsules for the encapsulation of insulinoma cells: biotransport and biocompatibility considerations. IEEE Trans Biomed Eng. 2001;48:1335–1341.
   PubMed Web of Science ®Google Scholar
• Freitas RA. Current status of nanomedicine and medical nanorobotics. J Comput Theoret Nanosci. 2005;2:1–25.
   Web of Science ®Google Scholar
• Lowery AR, Gobin AM, Day ES, et al. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomed. 2006;1(2):149–154.
   PubMed Web of Science ®Google Scholar
• Wakaskar RR. Cancer therapy with drug delivery systems. J Pharmacogeno Pharmacoproteom. 2017;8:100e1578.
   Google Scholar
• Wakaskar RR. Polymeric Micelles and their properties. J Nanomed Nanotechnol. 2017;8:1000433.
   Google Scholar